Celecoxib/tramadol

Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.^[1]

Celecoxib/tramadol

Combination of
Celecoxib	Nonsteroidal anti-inflammatory drug (NSAID)
Tramadol hydrochloride	Opioid agonist
Clinical data
Trade names	Seglentis
Other names	E-58425
License data	US DailyMed: Celecoxib_and_tramadol
Routes of administration	By mouth
ATC code	N02AJ16 (WHO)
Legal status
Legal status	US: Schedule IV[1]
Identifiers
KEGG	D12491

Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.^[1][2][3]